Start-up Sophia Genetics raises $30m for AI cancer diagnosis
Swiss start-up Sophia Genetics has raised $30m in a funding round led by London-based Balderton Capital, one Europe's largest venture capital firms, and featuring participation from 360 Capital Partners, Invoke Capital and Alychlo. Sophia Genetics, founded by a group of academics from Stanford University in 2011, uses artificial intelligence to analyse the human genome and diagnose a range of illnesses, including cancer and metabolic disorders. The company recently expanded to offer liquid biopsies through an app.

For free real time breaking news alerts sent straight to your inbox sign up to our breaking news emails Sign up to our free breaking news emails Please enter a valid email address Please enter a valid email address SIGN UP I would like to be emailed about offers, events and updates from The Independent. Read our privacy notice Thanks for signing up to the

Breaking News email {{ #verifyErrors }} {{ message }} {{ /verifyErrors }} {{ ^verifyErrors }} Something went wrong. Please try again later {{ /verifyErrors }}

A startup that’s using artificial intelligence to help analyse the human genome and then diagnose illnesses like cancer and metabolic disorders, has raised $30m in a recent funding round.

Sophia Genetics, which was founded in 2011 by academics from Stanford University and Switzerland, provides over 330 hospitals in more than 50 countries with software to analyse genomic profiles and diagnose patients.

It recently expanded into so-called liquid biopsies, offering an app that can help diagnose cancer by analysing DNA and tumour cells in blood, urine, cerebral spinal fluid and other liquid samples.

The latest funding round was led by London-based Balderton Capital, one of the largest venture capital firms in Europe. Balderton manages around $2.3bn in assets and has invested in more than 100 companies since 2000, including Betfair, before it publicly listed, and LOVEFiLM, before it was sold to Amazon in 2011.

Other investors that participated in the latest funding round include 360o Capital Partners, entrepreneur Mike Lynch’s Invoke Capital and Alychlo, which was started by Belgian pharmaceutical entrepreneur Marc Coucke.

“As diagnostic kits and sequencers become cheaper and more powerful, we believe that there is an opportunity to build the defining software layer on top of these technologies in genomics, just as Windows did for PCs and Android has for smartphones, and Sophia is already leading in this field,” said James Wise, a partner at Balderton Capital.

Jurgi Camblong, chief executive and co-founded of Sophia said that the group aims to break down the “information silos in healthcare, meaning that the information from a patient in London or Paris can for instance help better diagnose and treat a patient in Lagos or Rio”.